The patent landscape for RNAi 'gene silencing' - including CSIRO's hairpin RNAi technology - has been significantly clarified following the resolution of several opposition and re-examination cases i
Nanogen has announced it was issued Patent No. 6,960,298, "Mesoporous permeation layers for use on active electronic matrix devices" by the U.S. Patent and Trademark Office. The '298 patent re
Two researchers have announced receipt of a patent on the use of MSH analogs--chemicals that regulate fat storage and metabolism in the body.U.S. patent #6,716,810, awarded to Miles Brennan and Ute Hochgeschewender in April, is for the use of chemicals
Bionomics Limited has announced that it had filed a further international patent application that covers 496 proprietary angiogenesis drug t
Ingenium Pharmaceuticals AG has acquired outright US patents no. 5,994,075 and no. 6,015,670 from Incyte Corporation, the company announced today. Ingenium previously maintained
QLT Inc. has announced a ruling in the on-going litigation between plaintiff TAP Pharmaceutical Products, Inc. and its co-plaintiffs and defendants QLT USA, Inc. and Sanofi-Synthelabo Inc., a member of
Morphotek Inc. announced today the issuance of United States Patent 6,982,169 covering the use of chemical inhibitors to enhance evolution of target host cell genomes by reversibly regulating mismat
Advanced Biomaterial Systems, Inc. (ABS) has received U.S. patent 6,984,063 for an Apparatus for Mixing and Dispensing Components. This patent is a continuation of several patents which incorporate
The University of Rochester Medical Center and Vaccinex, Inc. announced today the award of a key U.S. patent for a technology platform that can assist researchers in finding new treatments for cancer and other diseases. While the technology has many
Sirna Therapeutics has announced that the United States Patent and Trademark Office (USPTO) has granted Sirna U.S. Patent No. 6,989,442 for the chemical synthesis and manufacturing of ribonucleic acids
TKT is conducting a clinical trial in Israel of its investigational gene-activated glucocerebrosidase (GA-GCB) for the treatment of Gaucher disease. Genzyme believes that TKT infringes Genzyme's patent by importing into Israel and using in Israel the GA-GCB product manufactured by the processes protected by Genzyme's patent.
A legal action of this type, which seeks standard remedies, is customary in the protection of intellectual property. Genzyme does not expect this action to adversely affect patients enrolled in TKT's ongoing clinical trial. Genzyme's patent covers novel culture processes that have been critical in enabling the company to produce Cerezyme(R) (imiglucerase for injection) on a large scale, which has ensured that the therapy is available to patients in need throughout the world.
One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Founded in 1981, Genzyme has grown from a small start-up to a diversified enterprise with annual revenues exceeding $2 billion and nearly 7,000 employees in locations spanning the globe. With many established products and services helping patients in more than 80 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopedics, cancer, transplant and immune diseases, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as heart disease and other areas of unmet medical need.
http://www.genzyme.com/